𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of plicamycin and hydroxyurea in acute myelogenous leukemia

✍ Scribed by Eric Archimbaud; Jacques Troncy; Catherine Sebban; Denis Guyotat; Yves Devaux; Martine French; Michel Moriceau; Jean-Jacques Viala; Denis Fiere

Publisher
Springer
Year
1989
Tongue
English
Weight
229 KB
Volume
25
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Amsa: A phase II trial in resistant and
Amsa: A phase II trial in resistant and recurrent acute myelogenous leukemia
✍ Boccia, Ralph ;Zighelboim, Jacob ;Champlin, Richard E. ;Kim, Chun Choo ;Gale, Ro πŸ“‚ Article πŸ“… 1984 πŸ› John Wiley and Sons 🌐 English βš– 186 KB

27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders

Therapy of the myeloid blast phase of ch
Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea
✍ TrοΏ½mper, Lorenz H. ;Ho, Anthony D. ;Hunstein, Werner ;Lelie, Hans ;Goudsmit, Rob πŸ“‚ Article πŸ“… 1989 πŸ› Springer-Verlag βš– 257 KB

Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology. Alternate-day plicamycin and hydroxyurea treatment was reported to induce remissions in the majority of patients with myeloid blast phase by Koller and Miller in 1986 Subsequently w

Treatment of terminal-phase chronic myel
Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyurea
✍ Dr M. Lazzarino; E. Morra; E. Brusamolino; E. P. Alessandrino; E. Orlandi; G. Pa πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 505 KB

We used intermediate doses of Ara-C (IDAra-C) in the treatment of 15 patients with chronic myelogenous leukemia (CML) in blast crisis and, combined with hydroxyurea, in 20 CML patients in accelerated phase. Patients with blastic CML received intensive 5-day courses of IDAra-C 600 mg/m2 every 12 h as